Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections
扎那米韦微针治疗流感感染
基本信息
- 批准号:10483904
- 负责人:
- 金额:$ 99.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-03-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AcuteAdamantaneAddressAgreementBlood CirculationCOVID-19 pandemicCenters for Disease Control and Prevention (U.S.)Cessation of lifeCharacteristicsClinicalCommunitiesDataDevelopmentDevelopment PlansDevicesDiseaseDoseDrug KineticsEffectivenessElderlyEngineeringEnsureEpidemicEpithelialFamily suidaeFormulationFutureHumanHydrogelsInfluenzaInfluenza preventionInhalationInhalation Drug AdministrationKineticsLightLiquid substanceLiteratureLungMedicalMethodsMiniature SwineModelingNeedlesNeuraminidase inhibitorOralOseltamivirPainPainlessPathogenicityPatientsPersonsPharmaceutical PreparationsPharmaceutical ServicesPharmacotherapyPhasePopulationPowder dose formPropertyPublishingPuncture procedureRattusResearchResistanceRespiratory SystemRiskRouteSafetySiteSkinSmall Business Innovation Research GrantSyringesSystemTherapeuticToxicologyTransdermal substance administrationVaccinationVaccinesVisitWorkabsorptionclinical developmenteconomic impacteffective therapyendonucleasefluinfluenza epidemicinfluenza infectioninfluenza outbreakinfluenza virus straininfluenzavirusinhibitormanufacturabilitymeetingsmortalitynovelnovel therapeuticspandemic diseasepatient populationpharmacokinetics and pharmacodynamicspreclinical studypreventproduct developmentprogramsprototyperesistant strainrespiratoryscale upseasonal influenzaskin barriertransmission processvaccine effectivenesszanamivir
项目摘要
Abstract
Yearly influenza epidemics strike millions of people, causing up to 500,000 deaths. Fatality caused by most
seasonal influenza viruses is <0.03%, but with significant mortality in the young and the elderly populations.
When a new pathogenic influenza strain enters the population, a pandemic could kill tens of millions of people
with a negative economic impact estimated to be over 150 billion dollars. Due to the incomplete efficacy of the
current vaccines, effective drug treatment is necessary. Presently, influenza treatment is only somewhat
effective, and some influenza strains are resistant to the currently marketed therapeutics, adamantanes and the
neuraminidase inhibitor Tamiflu®. However, while zanamivir (ZAN, Relenza®) remains highly active against
oseltamivir-resistant influenza strains, its therapeutic impact is severely limited by its route of administration, via
oral inhalation, which renders it unsuitable for patients with a compromised respiratory system. Therefore,
development of a novel delivery alternative for ZAN as we propose here, is poised to address a significant unmet
medical need.
Transdermal drug delivery offers a number of improvements over other delivery systems. The drug directly enters
the systemic circulation, circumventing absorption and first-pass barriers typical for oral delivery. It avoids skin
puncture by syringe needles, eliminating pain and patient visits to a clinician. Transdermal delivery of ZAN could
allow large numbers of patients to be reached during an influenza outbreak, which will be particularly important
in light of the added risk during the ongoing COVID-19 pandemic. While ZAN itself cannot cross the human skin
barrier at therapeutic rates, Microneedle (MN) - enhanced transdermal delivery is an elegant, efficient, and
painless method for increasing the skin permeation of many drugs, including ZAN. Our novel drug-device
combination product, TSR-066, consists of a swellable MN patch, which will continuously deliver ZAN over 5
days. This CRP proposal will support optimization and scale-up of the ZAN MN formulation and subsequent IND-
enabling toxicology studies in minipigs. We have obtained agreement with the FDA on the preclinical studies
needed in order to open the IND, as well as on the Phase I clinical development plans and the 505(b)2 regulatory
strategy. In addition to the experimental work proposed here, we will develop a robust IP expansion strategy for
the current ZAN MN product, as well as future product candidates that stand to benefit from MN-enabled delivery.
The end result of this work will be a novel, transdermal delivery approach for ZAN, which will expand its reach
into patient groups for which Relenza® is contraindicated and allow for simple administration for ZAN for both
treatment and prevention of the flu. We have assembled a team of expert advisors and collaborators to ensure
successful completion of this research plan.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elke Lipka其他文献
Elke Lipka的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elke Lipka', 18)}}的其他基金
Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu
用于治疗流感的新型扎那米韦自用微阵列贴片 (MAP)
- 批准号:
10761086 - 财政年份:2023
- 资助金额:
$ 99.99万 - 项目类别:
Microneedle Delivery of Trospium Chloride Optimized for Improved Tolerance and Patient Outcomes in Overactive Bladder Disease
优化曲司氯铵微针输送,改善膀胱过度活动症的耐受性和患者预后
- 批准号:
10546933 - 财政年份:2022
- 资助金额:
$ 99.99万 - 项目类别:
Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis
用于治疗脓毒症的合成高密度脂蛋白的开发
- 批准号:
10384700 - 财政年份:2022
- 资助金额:
$ 99.99万 - 项目类别:
Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis
用于治疗脓毒症的合成高密度脂蛋白的开发
- 批准号:
10569516 - 财政年份:2022
- 资助金额:
$ 99.99万 - 项目类别:
A Novel Combination Therapy to Treat Biofilm-based Pneumonia Infections
治疗生物膜肺炎感染的新型联合疗法
- 批准号:
9888308 - 财政年份:2019
- 资助金额:
$ 99.99万 - 项目类别:
New Prodrug Strategies for Cidofovir Designed for Mitigating First-Pass Metabolism
旨在减轻首过代谢的西多福韦新前药策略
- 批准号:
9436472 - 财政年份:2018
- 资助金额:
$ 99.99万 - 项目类别:
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.
开发 MRS-2541,一种甲硫氨酰-tRNA 合成酶抑制剂,用于治疗革兰氏阳性细菌感染。
- 批准号:
10699105 - 财政年份:2017
- 资助金额:
$ 99.99万 - 项目类别:
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections
扎那米韦微针治疗流感感染
- 批准号:
10614045 - 财政年份:2017
- 资助金额:
$ 99.99万 - 项目类别:
Microneedle Delivery of Zanamivir for Treatment of Influenza Infections
扎那米韦微针治疗流感感染
- 批准号:
9438857 - 财政年份:2017
- 资助金额:
$ 99.99万 - 项目类别:
相似海外基金
New Materials based on Adamantane
基于金刚烷的新材料
- 批准号:
550629-2020 - 财政年份:2020
- 资助金额:
$ 99.99万 - 项目类别:
University Undergraduate Student Research Awards
Modular approach to 1,2-disubstituted adamantane derivatives by directed C-H functionalization reactions
通过定向 C-H 官能化反应制备 1,2-二取代金刚烷衍生物的模块化方法
- 批准号:
315058126 - 财政年份:2016
- 资助金额:
$ 99.99万 - 项目类别:
Research Grants
Development of functional monolayers by successive coupling reaction originating from adamantane tripod on the metal surface
通过金属表面金刚烷三脚连续偶联反应开发功能单层
- 批准号:
24550155 - 财政年份:2012
- 资助金额:
$ 99.99万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Adamantane Drug Binding to Membrane-Bound Influenza A M2 Protein
金刚烷药物与膜结合甲型流感 M2 蛋白的结合
- 批准号:
8097038 - 财政年份:2011
- 资助金额:
$ 99.99万 - 项目类别:
On-chip supercontinuum generation and advanced spectroscopy on adamantane-type cluster molecules
金刚烷型簇分子的片上超连续谱生成和先进光谱
- 批准号:
511825862 - 财政年份:
- 资助金额:
$ 99.99万 - 项目类别:
Research Units